Abstract
No public abstract is available from the verified source records.
Manjusa Singh, Atifa Hafeez, Upasna Srivastava, Pankaj Singh, Manish Kumar Gupta
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The role of AI in drug discovery
10.1002/cbic.202300816 · 2024
Accurate structure prediction of biomolecular interactions with AlphaFold 3
10.1038/s41586-024-07487-w · 2024
Computational approaches for network-based integrative multi-omics analysis
10.3389/fmolb.2022.967205 · 2022
Revolutionizing healthcare: the role of artificial intelligence in clinical practice
10.1186/s12909-023-04698-z · 2023
Novel drug-target interactions via link prediction and network embedding
10.1186/s12859-022-04650-w · 2022
Prediction of effective drug combinations by an improved naïve Bayesian algorithm
10.3390/ijms19020467 · 2018
t-SNE based visualisation and clustering of geological domain
2016
A clustering and graph deep learning-based framework for COVID-19 drug repurposing
10.1016/j.eswa.2024.123560 · 2024
Network medicine: a network-based approach to human disease
10.1038/nrg2918 · 2011
A review on graph neural networks for predicting synergistic drug combinations
Provenance
crossref
Confidence 100%
ror
Confidence 99%
openalex
Confidence 95%
datacite
Confidence 0%
10.1007/s10462-023-10669-z · 2024
COMO: a pipeline for multi-omics data integration in metabolic modeling and drug discovery
10.1093/bib/bbad387 · 2023
Mass spectrometry-based proteomics as an emerging tool in clinical laboratories
10.1186/s12014-023-09424-x · 2023
Application of generative autoencoder in de novo molecular design
2018
Interpretation of network-based integration from multi-omics longitudinal data
10.1093/nar/gkab1200 · 2022
Glycoinformatics in the artificial intelligence era
10.1021/acs.chemrev.2c00110 · 2022
DNN-DTIs: improved drug-target interactions prediction using XGBoost feature selection and deep neural network
10.1016/j.compbiomed.2021.104676 · 2021
The rise of deep learning in drug discovery
10.1016/j.drudis.2018.01.039 · 2018
Construction and analysis of protein-protein interaction network of heroin use disorder
2019
Artificial intelligence for drug discovery: resources, methods, and applications
10.1016/j.omtn.2023.02.019 · 2023
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions
10.18632/oncotarget.9124 · 2016
Chapter 5: network biology approach to complex diseases
10.1371/journal.pcbi.1002820 · 2012
De novo drug design through artificial intelligence: an introduction
10.3389/frhem.2024.1305741 · 2024
Advances and trends in omics technology development
10.3389/fmed.2022.911861 · 2022
Machine learning in drug discovery: a review
10.1007/s10462-021-10058-4 · 2022
MolGAN: an implicit generative model for small molecular graphs
2018
Immunomics: a 21st century approach to vaccine development for complex pathogens
10.1017/s0031182015001079 · 2016
Mergeomics 2.0: a web server for multi-omics data integration to elucidate disease networks and predict therapeutics
10.1093/nar/gkab405 · 2021
Advances in integrated multi-omics analysis for drug-target identification
10.3390/biom14060692 · 2024
MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference
10.1038/s41598-023-33024-2 · 2023
Exploiting machine learning for end-to-end drug discovery and development
10.1038/s41563-019-0338-z · 2019
GCRNN: graph convolutional recurrent neural network for compound–protein interaction prediction
10.1186/s12859-022-04560-x · 2021
A guide to deep learning in healthcare
10.1038/s41591-018-0316-z · 2019
Whole exome and genome sequencing in mendelian disorders: a diagnostic and health economic analysis
10.1038/s41431-022-01162-2 · 2022
Revolutionizing drug discovery: an AI-powered transformation of molecular docking
10.1007/s00044-024-03253-9 · 2024
Can artificial intelligence accelerate preclinical drug discovery and precision medicine?
10.1080/17460441.2022.2090540 · 2022
Drugging the epigenome in the age of precision medicine
10.1186/s13148-022-01419-z · 2023
Immunomics in one health: understanding the human, animal, and environmental aspects of COVID-19
10.3389/fimmu.2024.1450380 · 2024
Metabolomics paves the way for improved drug target identification
10.15252/msb.202210914 · 2022
Democratized image analytics by visual programming through integration of deep models and small-scale machine learning
10.1038/s41467-019-12397-x · 2019
SMILES2vec: an interpretable general-purpose deep neural network for predicting chemical properties
2017
Application of pharmacokinetic-pharmacodynamic modeling in drug delivery: development and challenges
10.3389/fphar.2020.00997 · doi-reference
AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery
10.1186/s13195-020-00760-w · doi-reference
OmicsNet 2.0: a web-based platform for multi-omics integration and network visual analytics
10.1093/nar/gkac376 · doi-reference
Integrative clustering methods for multi-omics data
10.1002/wics.1553 · doi-reference
Integrative analysis of omics big data
10.1007/978-1-4939-7717-8_7 · doi-reference
Artificial intelligence in cancer target identification and drug discovery
10.1038/s41392-022-00994-0 · doi-reference
Lipidomics: techniques, applications, and outcomes related to biomedical sciences
10.1016/j.tibs.2016.08.010 · doi-reference
Network-based methods for prediction of drug-target interactions
10.3389/fphar.2018.01134 · doi-reference
LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters
10.1021/ci049885e · doi-reference
Applications of metabolomics in drug discovery and development
10.2165/00126839-200809050-00002 · doi-reference
ADME properties evaluation in drug discovery: prediction of Caco-2 cell permeability using a combination of NSGA-II and boosting
10.1021/acs.jcim.5b00642 · doi-reference
Epigenomics technologies and applications
10.1161/circresaha.118.310998 · doi-reference
Applications of machine learning in drug discovery and development
10.1038/s41573-019-0024-5 · doi-reference
Gene regulatory networks in disease and ageing
10.1038/s41581-024-00849-7 · doi-reference
Recent advances and application of generative adversarial networks in drug discovery, development, and targeting
10.1016/j.ailsci.2022.100045 · doi-reference
Machine learning for pharmacokinetic/pharmacodynamic modeling
10.1016/j.xphs.2023.01.010 · doi-reference
Clustering of small molecules: new perspectives and their impact on natural product lead discovery
10.3389/fntpr.2024.1367537 · doi-reference
Analysis of the uncharted, druglike property space by self-organizing maps
10.1007/s11030-021-10343-y · doi-reference
Random Forest: a classification and regression tool for compound classification and QSAR modeling
10.1021/ci034160g · doi-reference
Editorial: bioinformatics analysis of omics data for biomarker identification in clinical research, Volume II
10.3389/fgene.2023.1256468 · doi-reference
Deciphering signaling pathway networks to understand the molecular mechanisms of metformin action
10.1371/journal.pcbi.1004202 · doi-reference
Autoencoder-based drug-target interaction prediction by preserving the consistency of chemical properties and functions of drugs
10.1093/bioinformatics/btab384 · doi-reference
Multi-omics data integration, interpretation, and its application
10.1177/1177932219899051 · doi-reference
Molecular analysis and design using generative artificial intelligence via multi-agent modeling
10.1039/d4me00174e · doi-reference
Artificial intelligence, machine learning and deep learning in advanced robotics, a review
10.1016/j.cogr.2023.04.001 · doi-reference
Practical outcomes of applying ensemble machine learning classifiers to high-throughput screening (HTS) data analysis and screening
10.1021/ci800164u · doi-reference
Glycomics: a pathway to a class of new and improved therapeutics
10.1038/nrd1521 · doi-reference
Predicting drug-target interactions using Lasso with random forest based on evolutionary information and chemical structure
10.1016/j.ygeno.2018.12.007 · doi-reference
Improved protein structure prediction using potentials from deep learning
10.1038/s41586-019-1923-7 · doi-reference
Automating drug discovery
10.1038/nrd.2017.232 · doi-reference
Evolution of support vector machine and regression modeling in chemoinformatics and drug discovery
10.1007/s10822-022-00442-9 · doi-reference
DEEPScreen: high performance drug-target interaction prediction with convolutional neural networks using 2-D structural compound representations
10.1039/c9sc03414e · doi-reference
Nonlinear dimensionality reduction and mapping of compound libraries for drug discovery
10.1016/j.jmgm.2011.12.006 · doi-reference
Application of a kNN ‐based similarity method to biopharmaceutical manufacturing
10.1002/btpr.2945 · doi-reference
Using machine learning approaches for multi-omics data analysis: a review
10.1016/j.biotechadv.2021.107739 · doi-reference
Human protein–protein interaction networks: a topological comparison review
10.1016/j.heliyon.2024.e27278 · doi-reference
AI-powered therapeutic target discovery
10.1016/j.tips.2023.06.010 · doi-reference
Benchmarking algorithms for gene regulatory network inference from single-cell transcriptomic data
10.1038/s41592-019-0690-6 · doi-reference
Unraveling the molecular repertoire of tears as a source of biomarkers: beyond ocular diseases
10.1002/prca.201400084 · doi-reference
Integration strategies of multi-omics data for machine learning analysis
10.1016/j.csbj.2021.06.030 · doi-reference